MX2019008529A - Peptidos mimeticos de apolipoproteina c-ii (apoc-ii). - Google Patents

Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).

Info

Publication number
MX2019008529A
MX2019008529A MX2019008529A MX2019008529A MX2019008529A MX 2019008529 A MX2019008529 A MX 2019008529A MX 2019008529 A MX2019008529 A MX 2019008529A MX 2019008529 A MX2019008529 A MX 2019008529A MX 2019008529 A MX2019008529 A MX 2019008529A
Authority
MX
Mexico
Prior art keywords
apoc
mimetic peptides
mimetic
peptides
patient
Prior art date
Application number
MX2019008529A
Other languages
English (en)
Inventor
N Devalaraja Madhav
Thomas Remaley Alan
Shanker Ghosh Soumitra
O Sviridov Denis
Wolska Anna
Hung Lo Chih-
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2019008529A publication Critical patent/MX2019008529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a péptidos miméticos de apolipoproteína C-II (apoC-II) y métodos para tratar hipertrigliceridemia en un paciente con una cantidad efectiva de un péptido mimético de apoC-II.
MX2019008529A 2017-01-19 2018-01-19 Peptidos mimeticos de apolipoproteina c-ii (apoc-ii). MX2019008529A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US201762476531P 2017-03-24 2017-03-24
US201762476535P 2017-03-24 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Publications (1)

Publication Number Publication Date
MX2019008529A true MX2019008529A (es) 2020-02-07

Family

ID=62908746

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008529A MX2019008529A (es) 2017-01-19 2018-01-19 Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).

Country Status (14)

Country Link
US (2) US11136372B2 (es)
EP (1) EP3571216A4 (es)
JP (2) JP7353973B2 (es)
KR (1) KR20190121305A (es)
CN (1) CN110831957B (es)
AU (1) AU2018210404B2 (es)
BR (1) BR112019014707A2 (es)
CA (1) CA3050106A1 (es)
IL (2) IL268093B2 (es)
MX (1) MX2019008529A (es)
NZ (1) NZ755599A (es)
SG (2) SG10201911974UA (es)
TW (2) TW202130652A (es)
WO (1) WO2018136803A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008529A (es) 2017-01-19 2020-02-07 Us Health Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).
CN117580857A (zh) * 2021-06-23 2024-02-20 美国政府(由卫生和人类服务部的部长所代表) Apoc-ii短模拟肽及使用方法
WO2023215838A1 (en) * 2022-05-05 2023-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Short apolipoprotein e mimetic peptides and methods of use
US20240043499A1 (en) * 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
JP2005504085A (ja) 2001-09-28 2005-02-10 エスペリオン セラピューティクス，インコーポレイテッド 薬剤の局所投与による再狭窄の予防および治療
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
EP1587535A4 (en) * 2003-01-17 2010-02-24 Merck & Co Inc N-CYCLOHEXYLAMINOCARBONYL BENZENESULFONAMIDE DERIVATIVES
AU2004299486B2 (en) * 2003-12-15 2011-05-19 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
EP1719765A4 (en) * 2004-02-19 2009-01-07 Banyu Pharma Co Ltd NEW SULFONAMIDE DERIVATIVE
WO2006020040A2 (en) 2004-07-16 2006-02-23 Trustees Of Tufts College Apolipoprotein a1 mimetics and uses thereof
JP5143729B2 (ja) * 2005-06-29 2013-02-13 ハダジット メディカル リサーチ サービシズ アンド ディベラップメント リミテッド インスリン抵抗性及び２型糖尿病の予防のためのプロテインキナーゼｃ阻害剤
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20100016173A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009129263A1 (en) 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
US20120270771A1 (en) 2009-09-30 2012-10-25 Snu R&Db Foundation Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
MX364626B (es) 2012-11-06 2019-05-03 Les Hopitaux Univ De Geneve Péptidos miméticos.
MX2019008529A (es) 2017-01-19 2020-02-07 Us Health Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Also Published As

Publication number Publication date
IL279831A (en) 2021-03-01
NZ755599A (en) 2022-12-23
JP2023116739A (ja) 2023-08-22
AU2018210404A1 (en) 2019-08-08
WO2018136803A1 (en) 2018-07-26
JP2020511425A (ja) 2020-04-16
CN110831957A (zh) 2020-02-21
BR112019014707A2 (pt) 2020-04-07
KR20190121305A (ko) 2019-10-25
EP3571216A4 (en) 2020-11-04
EP3571216A1 (en) 2019-11-27
IL268093A (en) 2019-09-26
JP7353973B2 (ja) 2023-10-02
IL268093B2 (en) 2024-07-01
SG11201906422VA (en) 2019-08-27
SG10201911974UA (en) 2020-02-27
CA3050106A1 (en) 2018-07-26
TWI788323B (zh) 2023-01-01
US11827690B2 (en) 2023-11-28
TW201835097A (zh) 2018-10-01
TW202130652A (zh) 2021-08-16
US11136372B2 (en) 2021-10-05
AU2018210404B2 (en) 2022-01-27
US20210324043A1 (en) 2021-10-21
CN110831957B (zh) 2024-02-09
US20200140522A1 (en) 2020-05-07
WO2018136803A8 (en) 2019-08-01
IL268093B1 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CO2019009234A2 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas
MX2019008529A (es) Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
HK1255488A1 (zh) 組合t細胞激活和/或檢查點抑制劑治療癌症的肽和肽模擬物
EA201792245A1 (ru) Биоконъюгаты и их применения
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2016009500A (es) Transportador de la barrera hematoencefalica.
ZA201905851B (en) Peptides and methods for the treatment of diabetes
IL290414A (en) atf5 peptide variants and uses thereof
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
ZA202007822B (en) Immunodominant proteins and fragments in multiple sclerosis
SG11202006669RA (en) Peptides and uses thereof
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
IL275340A (en) Peptides and other active compounds to treat pain and increase pain sensitivity
SG11202111476RA (en) Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
EA201991491A1 (ru) Миметические пептиды apoc-ii
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
IL290643A (en) Peptides for transport and methods of using them
SG11201909851SA (en) Peptide for inducing regeneration of tissue, and use thereof
IL280450A (en) A peptide derived from cdca1 and a preparation containing it
GB2582571B (en) Peptides and use thereof
GB201810635D0 (en) Peptides and cancer treatment

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH